Banco Bilbao Vizcaya Argentaria S.A. Has $11.10 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Banco Bilbao Vizcaya Argentaria S.A. lifted its stake in Edwards Lifesciences Co. (NYSE:EW) by 13.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 149,596 shares of the medical research company’s stock after acquiring an additional 17,726 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Edwards Lifesciences were worth $11,098,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Evercore Wealth Management LLC acquired a new position in Edwards Lifesciences in the 4th quarter worth about $200,000. Adage Capital Partners GP L.L.C. grew its stake in shares of Edwards Lifesciences by 46.6% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,223,893 shares of the medical research company’s stock valued at $90,605,000 after buying an additional 389,141 shares in the last quarter. Syon Capital LLC acquired a new position in Edwards Lifesciences in the fourth quarter worth approximately $356,000. MGO One Seven LLC raised its position in Edwards Lifesciences by 16.3% during the fourth quarter. MGO One Seven LLC now owns 6,658 shares of the medical research company’s stock valued at $493,000 after acquiring an additional 931 shares in the last quarter. Finally, Dark Forest Capital Management LP lifted its stake in Edwards Lifesciences by 224.3% in the fourth quarter. Dark Forest Capital Management LP now owns 10,404 shares of the medical research company’s stock valued at $770,000 after acquiring an additional 7,196 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

EW has been the topic of a number of recent research reports. Barclays raised their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Morgan Stanley raised their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Evercore ISI decreased their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research note on Wednesday, February 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Finally, Truist Financial decreased their target price on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating for the company in a research report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have given a buy rating to the company. According to MarketBeat, Edwards Lifesciences has an average rating of “Hold” and an average target price of $79.25.

Edwards Lifesciences Trading Up 6.7 %

Shares of EW opened at $75.15 on Friday. The stock’s 50-day moving average price is $70.93 and its 200 day moving average price is $71.02. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $44.18 billion, a price-to-earnings ratio of 10.78, a P/E/G ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.04. The business had revenue of $1.41 billion for the quarter, compared to analysts’ expectations of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. During the same period in the previous year, the business posted $0.66 earnings per share. As a group, research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Activity

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the sale, the director now directly owns 60,372 shares in the company, valued at $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Bernard J. Zovighian sold 6,164 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.51, for a total value of $428,459.64. Following the transaction, the chief executive officer now owns 59,083 shares of the company’s stock, valued at $4,106,859.33. This represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,853 shares of company stock worth $5,163,062. 0.34% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.